EQS-Adhoc: Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued
Source: EQS
EQS-Ad-hoc: Disclosure of inside information pursuant to Article 17 of Regulation (EU) No 596/2014 Darmstadt,
Xevinapant is currently under clinical investigation and not approved for any indication anywhere in the world. Esther Döringer Stock exchanges: Regulated Market of Contact: Esther Döringer, Head of Media Relations End of Inside Information
|
Language: | English |
Company: | |
Frankfurter Str. 250 | |
64293 Darmstadt | |
Phone: | +49 (0)6151 72 - 2702 |
E-mail: | Friederike.Segeberg@merckgroup.com |
Internet: | https://www.merckgroup.com/de |
ISIN: | DE0006599905 |
WKN: | 659990 |
Indices: | DAX |
Listed: | Regulated Market in |
EQS News ID: | 1931843 |
End of Announcement |
|
1931843 24-Jun-